Harris Corporation (NYSE:HRS) has been awarded a 5-year, $43 million follow-on contract by the National Cancer Institute's Center for Cancer Research, continuing a legacy of providing comprehensive clinical data management for the Institute's intramural clinical trials program. The contract, which includes one base year and four one-year options, was awarded during the first quarter of Harris' fiscal 2017. Harris will continue to provide the expertise that drove increased data volume capacity and upheld high data quality within funding expectations under past contracts. This includes clinical data management, quality assurance and control, clinical audit and monitoring clinical trials for safety and compliance as well as research databases and systems enhancement. "The Harris team has consistently delivered increased data accuracy and improved program efficiencies for the National Cancer Institute for nearly 35 years," said Carl D'Alessandro, president, Harris Critical Networks. "Harris will build on this long legacy of innovation to deliver accurate and timely clinical data management support in full compliance with federal regulations." About Harris Corporation Harris Corporation is a leading technology innovator, solving customers' toughest mission-critical challenges by providing solutions that connect, inform and protect. Harris supports customers in more than 100 countries and has approximately $7.5 billion in annual revenue and 21,000 employees worldwide. The company is organized into four business segments: Communication Systems, Space and Intelligence Systems, Electronic Systems and Critical Networks. Learn more at harris.com. Forward-Looking Statements This press release contains forward-looking statements that reflect management's current expectations, assumptions and estimates of future performance and economic conditions. Such statements are made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The company cautions investors that any forward-looking statements are subject to risks and uncertainties that may cause actual results and future trends to differ materially from those matters expressed in or implied by such forward-looking statements. Statements about the value or expected value of orders, contracts or programs are forward-looking and involve risk and uncertainties. Harris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.